2015 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
01/19/15Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairs
Company also announces promotions of Peter Weiler and Linda AngaritisMISSISSAUGA, ON, Jan. 19, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the appointment of Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceutical industry, conducting clinic... 
Printer Friendly Version
01/09/15Cipher Pharmaceuticals acquires assets of Melanovus Oncology Inc.
MISSISSAUGA, ON, Jan. 9, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has acquired the assets of Melanovus Oncology Inc. ("Melanovus"), a Hershey (Pennsylvania)-based life sciences company. The assets include seven pre-clinical compounds for the treatment of melanoma and other cancers. Founded in 2012, Melanovus acquired an exclusive global license to a library of compounds and related intellectual property from the Penn State Res... 
Printer Friendly Version
01/07/15Cipher Pharmaceuticals acquires Canadian commercialization rights to novel antibacterial compound Ozenoxacin
- Company expands Canadian dermatology portfolio – MISSISSAUGA, ON, Jan. 7, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that it has licensed the Canadian rights to Ozenoxacin, a topical treatment for adult and paediatric patients with impetigo, from Ferrer, a privately-held Spanish pharmaceutical company. In 2013, Ferrer successfully completed a first phase III clinical trial of Ozenoxacin in adult and paediatric patients aged two y... 
Printer Friendly Version
<< First | Previous | Next | Last >>